MedTrace Logo

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

NCT03060850 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2019-02-01

No results posted yet for this study

Summary

This is an open label, dose escalation, phase I study to determine the recommended Phase 2 dose (PR2D) by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma.

Conditions

Interventions

DRUG

AC0010MA

Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days

Sponsors & Collaborators

  • Hangzhou ACEA Pharmaceutical Research Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jie Jin, MD · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2019-12-14
Completion
2020-12-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03060850 on ClinicalTrials.gov